Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs – α-adrenergic blockers and 5α-reductase inhibitors – are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.
- 5α reductase inhibitor
- CombAT trial
- benign prostatic hyperplasia
- combination therapy benign prostatic hyperplasia
- fixed-dose benign prostatic hyperplasia
- lower urinary tract symptoms
- α-adrenergic blocker